Cordis US Corp

Cordis US Corp, Cordis US Division, is a for-profit manufacturer of cardiovascular and endovascular medical devices that supplies specialized catheters, stents, guide wires, and vascular closure devices to the Defense Logistics Agency Troop Support Medical as a prime contractor, with 99.9% of recent awards flowing through a single indefinite delivery vehicle operating on full-and-open, non-set-aside procurement.

Cordis US Corp is headquartered in Hialeah, Florida, with manufacturing and fulfillment operations in Miami Gardens, Florida. The company is a subsidiary of Cardinal Health and competes as a for-profit manufacturer primarily under NAICS 339112 (Surgical and Medical Instrument Manufacturing) and 425410 (Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers), with no SBA set-aside designations across its federal footprint. The vendor operates as a 100% prime contractor with negligible subcontracting activity.

Cordis US's federal business is dominated by a single customer and vehicle: the Defense Logistics Agency Troop Support Medical accounts for 842 of 848 awards (99.3%) and $31.8 million of $32.1 million in combined potential value. Nearly all work flows through an indefinite delivery contract (SPE2DE23DA007) established in March 2023 with a ceiling of $26.2 million and performance period running through March 2028. The delivery orders under this vehicle are small-dollar, short-cycle procurements for specific medical devices — representative orders include a $4,459.85 delivery order for SI Brite Tip F5 23cm catheters (June 2026), a $2,612.82 delivery order for 6F .070 AL 2 100cm guide wires (June 2026), and an $44,261.76 delivery order for a PRECISE PRO RX US Carotid System (November 2025). The vendor also holds a smaller single-award indefinite delivery contract with the Department of Veterans Affairs Veterans Integrated Service Network 5 (ceiling $132,377, awarded November 2025 through November 2030) for SMART CONTROL stent models supplied on consignment to the Hershel "Woody" Williams VAMC in Huntington, West Virginia.

Activity has grown sharply from 1 award in 2017 to 301 awards in 2025, driven by the ramp-up of the DLA IDV. Award frequency remained high in the first seven months of 2026 (147 awards), but the recompete cliff is minimal — only 1 award with ultimate completion in the next twenty-four months carries $25 thousand in potential value, reflecting the structured, multi-year renewal of the DLA IDV through March 2028. The secondary customer base is negligible: the Defense Health Agency has placed 3 awards ($133 thousand), and Veterans Health Administration Veterans Integrated Service Network 5 and 1 account for the remaining 3 awards ($159 thousand combined). Combined dollars obligated across all awards total $805 thousand, representing only 3% of combined potential value, indicating that most awards carry ceilings rather than executed spend.

Cordis US Corp's federal footprint is narrow and specialized — it manufactures and supplies advanced cardiovascular intervention equipment exclusively to defense and veterans' healthcare systems through delivery orders placed against two IDVs. The vendor has no recorded subcontractor relationships in the source data and does not sit on GWACs, BPAs, or agency-wide vehicles beyond the two named IDVs. The product portfolio centers on catheters (Infiniti, TEMPO, AVANTI+, and SI Brite Tip families), guide wires (Storq, DGW), vascular closure devices, and specialized intervention systems (PRECISE PRO RX Carotid System, SMART Control stents). All work is performed in Miami Gardens, Florida, and pricing is fixed-price with economic price adjustment across the federal footprint.